Israel is unlikely to withdraw its troops from the enclave before Hamas and other militant groups lay down their arms. By Adam Rasgon Natan Odenheimer and Abu Bakr Bashir Adam Rasgon and Natan ...

Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs. The agreement ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Bristol Myers Squibb is leaning heavily on its newer key products, grouped into its growth portfolio category, to weather the storm it expects as it heads toward further declines within its legacy ...

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake. Bristol Myers Squibb sales hit $12.5 ...